HCLS

HealthVerity recognized in three 2023 Gartner® Hype Cycle™ reports

Retrieved on: 
Tuesday, February 13, 2024

PHILADELPHIA, Feb. 13, 2024 /PRNewswire/ -- HealthVerity, the leader in synchronizing transformational technologies and real-world data (RWD) to advance the science, today announced that it was recognized in three of the July 2023 Gartner Hype Cycles titled: Hype Cycle for Life Science Clinical Development, 2023, Hype Cycle for Life Science Commercial Operations, 2023, and Hype Cycle for Healthcare Data, Analytics and AI, 2023. This is the second year in a row that the company has been recognized in all three of these Hype Cycles and the third consecutive year for Life Science Commercial Operations.

Key Points: 
  • Recognized for Life Science Clinical Development, Life Science Commercial Operations, and Healthcare Data, Analytics and AI
    PHILADELPHIA, Feb. 13, 2024 /PRNewswire/ -- HealthVerity, the leader in synchronizing transformational technologies and real-world data (RWD) to advance the science, today announced that it was recognized in three of the July 2023 Gartner Hype Cycles titled: Hype Cycle for Life Science Clinical Development, 2023, Hype Cycle for Life Science Commercial Operations, 2023, and Hype Cycle for Healthcare Data, Analytics and AI, 2023.
  • HealthVerity offers patient data tokenization services with HealthVerity Identity Manager , a leading patient matching and identity resolution technology that is 10x more accurate than legacy tokenization technologies.
  • "We are excited to be recognized by Gartner in the Hype Cycle reports," said HealthVerity COO Andrew Goldberg.
  • We believe our inclusion in the Gartner Hype Cycle reports demonstrates the difference these solutions can have on advancing the science."

WNS Discloses Client Intent to Terminate

Retrieved on: 
Friday, February 2, 2024

WNS (Holdings) Limited (WNS) (NYSE: WNS), a leading provider of global Business Process Management (BPM) solutions, today disclosed in its Form 6-K filed with the SEC the following information in Part III Risk Factors:

Key Points: 
  • WNS (Holdings) Limited (WNS) (NYSE: WNS), a leading provider of global Business Process Management (BPM) solutions, today disclosed in its Form 6-K filed with the SEC the following information in Part III Risk Factors:
    “For example, one of our top five customers by revenue contribution in fiscal 2024, which is in the HCLS SBU, served a termination notice on January 31, 2024.
  • The customer accounted for 4.1%, 6.5% and 7.3% of our revenue and 4.3%, 6.8% and 7.9% of our revenue less repair payments (non-GAAP) in fiscal 2024, fiscal 2023 and fiscal 2022, respectively.
  • This termination is effective July 1, 2024, and does not impact our revenue in fiscal 2024.
  • We are in discussion with the customer around the support required for the transition of the services and are currently ascertaining the related financial and accounting impact.”

Quantiphi and Lambda Announce Partnership to Accelerate AI Innovation

Retrieved on: 
Wednesday, January 10, 2024

MARLBOROUGH, Mass., Jan. 10, 2024 /PRNewswire/ -- Quantiphi , a leading AI-first digital engineering company and Lambda , the GPU cloud and AI infrastructure company founded by deep learning engineers, have partnered to provide tailored AI solutions to enterprise customers and digital AI natives across multiple industries.

Key Points: 
  • MARLBOROUGH, Mass., Jan. 10, 2024 /PRNewswire/ -- Quantiphi , a leading AI-first digital engineering company and Lambda , the GPU cloud and AI infrastructure company founded by deep learning engineers, have partnered to provide tailored AI solutions to enterprise customers and digital AI natives across multiple industries.
  • The synergy between Quantiphi's AI capabilities and Lambda's high-speed computing infrastructure lies at the heart of this collaboration.
  • Quantiphi , known for developing cutting-edge generative AI solutions, and Lambda are addressing this growing need.
  • "This collaboration bridges the gap between Quantiphi's AI prowess and Lambda's high-performance GPU cloud, unlocking new possibilities for AI-driven innovation.

Medicom Technologies Named as a Sample Vendor in Two Gartner® Hype Cycle™ Reports

Retrieved on: 
Monday, September 18, 2023

RALEIGH, N.C., Sept. 18, 2023 /PRNewswire/ -- For the second consecutive year, Medicom Technologies, Inc. ( Medicom ) proudly announces its inclusion as a Sample Vendor in two highly anticipated Gartner Hype Cycle reports for Health Care and Life Sciences (HCLS) organizations.

Key Points: 
  • RALEIGH, N.C., Sept. 18, 2023 /PRNewswire/ -- For the second consecutive year, Medicom Technologies, Inc. ( Medicom ) proudly announces its inclusion as a Sample Vendor in two highly anticipated Gartner Hype Cycle reports for Health Care and Life Sciences (HCLS) organizations.
  • The recently published reports in July 2023 showcase Medicom's instrumental role in the evolving landscape of data monetization within the healthcare sector.
  • Medicom is featured in the Gartner Hype Cycle for Healthcare Data, Analytics, and AI, 2023, as well as the Gartner Hype Cycle for Life Science Clinical Development, 2023.
  • Medicom's repeat inclusion as a Sample Vendor in these reports serves as a testament to its pivotal role in facilitating groundbreaking research aimed at improving patient outcomes.

Uniphore Recognized in Ten Gartner® Hype Cycle™ Reports

Retrieved on: 
Tuesday, August 29, 2023

Uniphore , one of the world’s largest AI-native, enterprise SaaS companies, today announced that it has been recognized in ten Gartner Hype Cycle reports focused on the critical AI and analytics technologies that are driving rapid innovation across enterprise organizations worldwide.

Key Points: 
  • Uniphore , one of the world’s largest AI-native, enterprise SaaS companies, today announced that it has been recognized in ten Gartner Hype Cycle reports focused on the critical AI and analytics technologies that are driving rapid innovation across enterprise organizations worldwide.
  • Gartner Hype Cycle reports provide a graphic representation of the maturity and adoption of technologies and applications, and how they are potentially relevant to solving real business problems and exploiting new opportunities.
  • CV and signal analysis have been used for years to support neuromarketing research to test reactions to products and ads.
  • Gartner clients can read the additional Gartner Hype Cycle reports that include Uniphore as a Sample Vendor in the Gartner portal, including the 2023 reports for:

hc1 Provides Thought Leadership on Unlocking the Value of Lab Data During 2023 AACC Annual Scientific Meeting & Clinical Lab Expo

Retrieved on: 
Thursday, July 6, 2023

INDIANAPOLIS , July 6, 2023 /PRNewswire/ -- hc1, a leader in identifying real-time insights and risk signals in complex laboratory data, will be offering a Lecture Series Presentation at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo taking place in Anaheim, Calif., July 23-27, 2023.

Key Points: 
  • An estimated 80% of medical data collected today does not benefit patient care after the encounter, but labs are in the ideal position to lead the charge, because of the amount and type of data in their care.
  • The pair will share how by leveraging the power of  AWS, hc1 is helping lab managers gain visibility into overall performance and extend their capabilities to optimize operations, proactively engage with their customers and inform testing and treatment decisions.
  • In addition to attending the presentation, Clinical Lab Expo attendees are invited to meet the hc1 team in Booth #970 where a prototype of hc1's Workforce Optimization solution will be available for demonstration.
  • For more information on the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo and to secure a spot, visit here .

Quantiphi Eliminates Need for Animal Testing, Transforms Drug Testing with Digital Animal Replacement Technology (DART)

Retrieved on: 
Wednesday, June 28, 2023

The FDA Modernization Act 2.0 , signed by US President Biden on Dec. 29, 2022, overturned the previous requirement of animal testing in new drug development, causing a surge in the quest for alternative methods for drug testing and biological products.

Key Points: 
  • The FDA Modernization Act 2.0 , signed by US President Biden on Dec. 29, 2022, overturned the previous requirement of animal testing in new drug development, causing a surge in the quest for alternative methods for drug testing and biological products.
  • Animal testing has been a long-standing ethical concern, and a study estimated that each year in the US, more than 115 million animals are killed for experimentation.
  • Quantiphi Global Leader in Healthcare and Life Science (HCLS), Bruno Nardone said Quantiphi pioneered DART, an innovative, AI-based solution by combining the potential of human biology and advanced digital technologies to accurately predict drug safety and efficacy, reducing animal testing and sacrifice in testing.
    "
  • "DART uses ethically sourced human stem cells, a Digital Workstation, and artificial intelligence (AI) to predict drug safety based on stem cell-drug interactions.

Quantiphi Eliminates Need for Animal Testing, Transforms Drug Testing with Digital Animal Replacement Technology (DART)

Retrieved on: 
Wednesday, June 28, 2023

The FDA Modernization Act 2.0 , signed by US President Biden on Dec. 29, 2022, overturned the previous requirement of animal testing in new drug development, causing a surge in the quest for alternative methods for drug testing and biological products.

Key Points: 
  • The FDA Modernization Act 2.0 , signed by US President Biden on Dec. 29, 2022, overturned the previous requirement of animal testing in new drug development, causing a surge in the quest for alternative methods for drug testing and biological products.
  • Animal testing has been a long-standing ethical concern, and a study estimated that each year in the US, more than 115 million animals are killed for experimentation.
  • Quantiphi Global Leader in Healthcare and Life Science (HCLS), Bruno Nardone said Quantiphi pioneered DART, an innovative, AI-based solution by combining the potential of human biology and advanced digital technologies to accurately predict drug safety and efficacy, reducing animal testing and sacrifice in testing.
    "
  • "DART uses ethically sourced human stem cells, a Digital Workstation, and artificial intelligence (AI) to predict drug safety based on stem cell-drug interactions.

Dataiku Named Snowflake’s Partner of the Year 3rd Time in a Row, Now Runs in New Snowpark Container Services

Retrieved on: 
Tuesday, June 27, 2023

Snowpark Container Services enable Dataiku to provide an accessible, collaborative, and scalable environment with the Snowflake Data Cloud, unlocking the potential of data, analytics, and AI projects, including generative AI initiatives for customers.

Key Points: 
  • Snowpark Container Services enable Dataiku to provide an accessible, collaborative, and scalable environment with the Snowflake Data Cloud, unlocking the potential of data, analytics, and AI projects, including generative AI initiatives for customers.
  • Simultaneously, Dataiku takes pride in being named Snowflake's Machine Learning/AI Partner of the Year for 2023 for the third consecutive year.
  • Dataiku is one of multiple organizations that are already using Snowpark Container Services to deliver sophisticated applications.
  • Visit Dataiku at Snowflake Summit from June 26-29 at booth 1320 or attend one of our sessions:

RCH Solutions Announces Hiring of Jason Winters as Director of Services

Retrieved on: 
Friday, March 31, 2023

WAYNE, Pa.,  March 31, 2023 /PRNewswire-PRWeb/ --RCH Solutions (RCH), a global provider of Bio-IT computing expertise for Life Sciences and Healthcare firms of all sizes, is pleased to announce the hiring of Jason Winters as Director of Services. Jason brings more than 20 years of experience leading customer experience teams in the design, execution and delivery of IT services for clients in the pharmaceutical, and biotech sectors. In this role, Mr. Winters will be responsible for leading and growing the company's comprehensive Bio-IT services stack, including their Sci-T Consulting Services, Professional Services and Managed Services, under the direction of Chief Technology Officer, Phil Eschallier.

Key Points: 
  • WAYNE, Pa., March 31, 2023 /PRNewswire-PRWeb/ -- RCH Solutions (RCH), a global provider of Bio-IT computing expertise for Life Sciences and Healthcare firms of all sizes, is pleased to announce the hiring of Jason Winters as Director of Services.
  • Jason brings more than 20 years of experience leading customer experience teams in the design, execution and delivery of IT services for clients in the pharmaceutical, and biotech sectors.
  • In this role, Mr. Winters will be responsible for leading and growing the company's comprehensive Bio-IT services stack, including their Sci-T Consulting Services , Professional Services and Managed Services , under the direction of Chief Technology Officer, Phil Eschallier.
  • "I am thrilled to be joining RCH Solutions," said Jason Winters.